World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 27 May 2013
Main ID:  NTR2851
Date of registration: 13/04/2011
Primary sponsor: Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
Public title: Expressie van CCL25 en CCR9 bij inflammatoire darmziekten en primaire scleroserende cholangitis.
Scientific title: Expression of CCL25 and CCR9 in human colon in IBD/PSC patients. - PSColon
Date of first enrolment: 1/5/2009
Target sample size: 80
Recruitment status: recruiting
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2851
Study type:  observational
Study design:  Randomised: No; Masking: None; Control: [default]; Group: Parallel; Type: 2 or more arms, non-randomized  
Countries of recruitment
The Netherlands
Contacts
Name: C. IJ.  Ponsioen
Address:  Dept. Gastroenterology and Hepatology Academic Medical Center Amsterdam PO Box 22660 1100 DD Amsterdam The Netherlands
Telephone:
Email: c.y.ponsioen@amc.uva.nl
Affiliation: 
Name: K.  Boonstra
Address:  PO Box 22660, Dept. Gastroenterology and Hepatology Room C2-231 Academic Medical Center Amsterdam 1100 DD Amsterdam The Netherlands
Telephone:
Email: k.boonstra@amc.uva.nl
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Newly diagnosed PSC patients screened for IBD, ≥18 yr old;

2. a. Newly diagnosed UC patients, ≥18 yr old;

2. b. Infectious enterocolitis patients (bacterial/viral/parasitic), ≥18 yr old;

3. PSC/UC surveillance patients, ≥18 yr old;

4. UC surveillance patients, ≥18 yr old;

5. Controls referred for CRC screening, ≥18 yr old.

Exclusion criteria: 1. Inability to give informed consent;

2. Bleeding diathesis.


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Crohn's disease, Ulcerative Colitis, Inflammatory bowel disease, Primary sclerosing cholangitis

Intervention(s)
Ileal and colonic biopsies during colonoscopy.
Primary Outcome(s)
Expression of CCL25 in human colon.
Secondary Outcome(s)
1. Semiquantitative analyses of CCL25 and/or CCR9+ lymphocytes in double stained colonic biopsies between patients and controls;

2. Quantitative analyses of CCL25 mRNA in colon of patients and controls;

3. Quantitative analyses α4β7/CCR9+ T cells in peripheral blood.
Secondary ID(s)
MEC 09/059
Source(s) of Monetary Support
Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history